__NUXT_JSONP__("/drugs/Zamtocabtagene_Autoleucel", (function(a,b,c,d){return {data:[{drug:{slug:b,emaEpar:[],fdaDrugLabel:[],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"A preparation of autologous CD4\u002FCD8 enriched T-lymphocytes engineered to express pLTG1497, a tandem chimeric antigen receptor (CAR) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, with potential immunostimulating and antineoplastic activities. Upon administration, zamtocabtagene autoleucel target and bind to CD19- and CD20-expressing tumor B-cells. This induces selective toxicity in tumor B-cells expressing these TAAs. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.",fdaUniiCode:"NT3BAN5MDV",identifier:"C180596",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C129826","C137999","C28681"],synonyms:["Autologous Anti-CD20\u002FCD19-targeting Tandem CAR T Cells MB-CART2019.1","Autologous pLTG1497-transduced CAR T-cells MB-CART2019.1","MB CART2019.1","MB-CART2019.1","MBCART2019.1","ZAMTOCABTAGENE AUTOLEUCEL",c]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FZamtocabtagene_Autoleucel",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("","Zamtocabtagene_Autoleucel","Zamtocabtagene Autoleucel","2021-10-30T13:36:43.273Z")));